RxDoctor Payments Data

Gillian Lowe, MD

Family Medicine · Edgewater, MDNPI 1841510161

Payments from drug & device makers

$407in general payments, 2019–2025

Across 18 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$194
  • AbbVie$72
  • Amgen$47
  • Novo Nordisk$38
  • Novartis$24
  • Lilly USA, LLC$19
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$37793%
  • Education$307%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences8$194
AbbVie(2 entities)3$72
Amgen2$47
Novo Nordisk2$38
Novartis1$24
Lilly USA, LLC1$19
Irhythm Technologies, Inc.1$13

How this compares

$407 in reported general payments places this provider in the 50th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$208,447
Medicare patients
411
Services billed
2,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$54,677
MounjaroTirzepatide32$51,764
OzempicSemaglutide49$50,505
EliquisApixaban52$44,197
XareltoRivaroxaban16$13,443
JanuviaSitagliptin Phosphate14$13,016
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,707
Valsartan187$8,952
Rosuvastatin Calcium247$6,742
Atorvastatin Calcium388$5,968
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,526
Levothyroxine Sodium290$3,340
Bupropion XlBupropion Hcl71$3,194
Metoprolol Succinate158$3,098
Losartan Potassium267$2,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$19$51,76432 claims
Novo NordiskOzempic$38$50,50549 claims
AbbVieSynthroid$72$1,11630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Edgewater

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →